Epithelial-to-mesenchymal transition and invadopodia markers in breast cancer: Lumican a key regulator
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
A great hallmark of breast cancer is the absence or presence of estrogen receptors ERα and ERβ, with a dominant role in cell proliferation, differentiation and cancer progression. Both receptors are related with Epithelial-to-Mesenchymal Transition (EMT) since there is a relation between ERs and extracellular matrix (ECM) macromolecules expression, and therefore, cell-cell and cell-ECM interactions. The endocrine resistance of ERα endows epithelial cells with increased aggressiveness and induces cell proliferation, resulting into a mesenchymal phenotype and an EMT status. ERα signaling may affect the transcriptional factors which govern EMT. Knockdown or silencing of ERα and ERβ in MCF-7 and MDA-MB-231 breast cancer cells respectively, provoked pivotal changes in phenotype, cellular functions, mRNA and protein levels of EMT markers, and consequently the EMT status. Mesenchymal cells owe their migratory and invasive properties to invadopodia, while in epithelial cells, lamellipodia and filopodia are mostly observed. Invadopodia, are actin-rich protrusions of plasma membrane, promoting proteolytic degradation of ECM and tumor invasion. Cortactin and MMP-14 govern the formation and principal functions of invadopodia. In vitro experiments proved that lumican inhibits cortactin and MMP-14 expression, alters the formation of lamellipodia and transforms mesenchymal cells into epithelial-like. Conclusively, lumican may inhibit or even reverse the several metastatic features that EMT endows in breast cancer cells. Therefore, a lumican-based anti-cancer therapy which will pharmacologically target and inhibit EMT might be interesting to be developed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Extracellular matrix structure
Theocharis, A. D., Skandalis, S. S., Gialeli, C., & Karamanos, N. K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.001 · Cited by 2,598
Gaggioli, C., Hooper, S., Hidalgo-Carcedo, C., Grosse, R., Marshall, J. F., Harrington, K., & Sahai, E. (2007) · Nature Cell Biology · doi:10.1038/ncb1658 · Cited by 1,589
Chakravarti, S., Magnuson, T., Lass, J. H., Jepsen, K. J., LaMantia, C., & Carroll, H. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.141.5.1277 · Cited by 731
Foot and mouth: podosomes, invadopodia and circular dorsal ruffles
Buccione, R., Orth, J. D., & McNiven, M. A. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1436 · Cited by 594
The Arp2/3 complex is required for lamellipodia extension and directional fibroblast cell migration
Suraneni, P., Rubinstein, B., Unruh, J. R., Durnin, M., Hanein, D., & Li, R. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201112113 · Cited by 337
Nucleus–Invadopodia Duo During Cancer Invasion
Ferrari, R., Infante, E., & Chavrier, P. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.11.006 · Cited by 41
Cited by
Tumor Microenvironment: Extracellular Matrix Alterations Influence Tumor Progression
Brassart-Pasco, S., Brézillon, S., Brassart, B., Ramont, L., Oudart, J.-B., & Monboisse, J. C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00397 · Cited by 335
Self-citationDatta, A., Deng, S., Gopal, V., Yap, K. C.-H., Halim, C. E., Lye, M. L., Ong, M. S., Tan, T. Z., Sethi, G., Hooi, S. C., et al. (2021) · Cancers · doi:10.3390/cancers13081882 · Cited by 184
The Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited
Dzobo, K., Senthebane, D. A., & Dandara, C. (2023) · Cancers · doi:10.3390/cancers15020376 · Cited by 146
Lumican promotes calcific aortic valve disease through H3 histone lactylation
Huang, Y., Wang, C., Zhou, T., Xie, F., Liu, Z., Xu, H., Liu, M., Wang, S., Li, L., Chi, Q., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae407 · Cited by 124
Metadata
- Authors
- Karamanou, K., Franchi, M., Vynios, D., & Brézillon, S.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 62
- Pages
- 125-133
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2968818721
- Cited by
- 151
- References
- 7
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epithelial-to-mesenchymal transition and invadopodia markers in breast cancer: Lumican a key regulator. https://app.cochat.ai/papers/10.1016/j.semcancer.2019.08.003
- The paper
- Karamanou, K., Franchi, M., Vynios, D., & Brézillon, S. (2020). Epithelial-to-mesenchymal transition and invadopodia markers in breast cancer: Lumican a key regulator. Seminars in Cancer Biology. https://doi.org/10.1016/j.semcancer.2019.08.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.